NEW YORK, Dec. 3, 2019 /PRNewswire/ -- WeissLaw
LLP is investigating possible breaches of fiduciary duty and
other violations of law by the Board of Directors of Audentes
Therapeutics, Inc. ("Audentes" or the "Company") (NASDAQ: BOLD) in
connection with the proposed acquisition of the Company by Astellas
Pharma Inc. ("Astellas Pharma") (OTC:ALPMY). Under the terms
of the acquisition agreement, BOLD shareholders will receive
$60.00 per share in cash.
If you are a shareholder and wish to discuss
this investigation or have any questions concerning this notice or
your rights or interests, visit our website:
https://weisslawllp.com/audentes-therapeutics-inc-investigation/
Or please contact:
Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY 10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com
WeissLaw is investigating whether Audentes' Board acted to
maximize shareholder value prior to entering into the acquisition
agreement. Notably, the deal gives Astellas access to AT132,
the Company's lead gene replacement therapy program, which has
shown a promising safety and efficacy profile in patients with a
rare neuromuscular disorder. Finally, the merger agreement
has a "No Solicitation" provision barring Audentes from discussing
any acquisition proposals from another party.
Given these facts, WeissLaw is concerned whether the proposed
acquisition undervalues the Company, and whether all material
information related to the proposed acquisition is fully and fairly
disclosed.
WeissLaw LLP has litigated hundreds of stockholder class and
derivative actions for violations of corporate and fiduciary
duties. We have recovered over a billion dollars for
defrauded clients and obtained important corporate governance
relief in many of these cases. If you have information or
would like legal advice concerning possible corporate wrongdoing
(including insider trading, waste of corporate assets, accounting
fraud, or materially misleading information), consumer fraud
(including false advertising, defective products, or other
deceptive business practices), or anti-trust violations, please
email us at stockinfo@weisslawllp.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-investigates-audentes-therapeutics-inc-300968707.html
SOURCE WeissLaw LLP